Ways to disseminate device safety information considered
This article was originally published in The Silver Sheet
Executive Summary
FDA is scrutinizing ways to release device safety information to the public, seeking to be timely without sacrificing completeness and accuracy. "The historical strategy of waiting to communicate until the end of a lengthy evaluation and negotiation process doesn't work," says Nancy Ostrove, senior advisor for risk communication in FDA's Office of Planning. Patients and doctors want information earlier than ever before, she says, yet risk assessment remains a lengthy and complex process. Consequently, FDA and manufacturers walk a "parallel tightrope," making judgments based on less-than-complete data and deciding how and when to communicate that data to the public. FDA has never systematically analyzed how the public receives and interprets safety information. That task will be the primary mission of the new 15-member Risk Communication Advisory Committee, set to convene for the first time early this year ("The Silver Sheet" November 2007)
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.